India's Sun Pharmaceutical Industries Ltd. on Tuesday said it has started the process of integrating its opiates business in Australia.
The company had completed the acquisition of the opiates business from GlaxoSmithKline (GSK).
Sun Pharma announced the acquisition in March 2015.
According to Sun Pharmaceuticals, the acquisition fortifies the company's global position with two opiates manufacturing facilities in Port Fairy and Latrobe (both in Australia) complementing its current active pharmaceutical ingredients (API) manufacturing footprint globally.
Sun Pharma now offers a rich basket of opiates product line in addition to a large API portfolio and dosage formulations covering a broad range of chronic and acute prescription drugs.
It also brings a specialised team to drive business growth.
The acquisition enables Sun Pharma to expand its narcotics raw material (NRM) market share and enhance opiate alkaloids portfolio.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app